(EN) A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy
MK-2870-005 (ENGOT-en23/GOG-3095)
NCT06132958
 Actif en recrutement
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI
|
Endomètre |
Dr José Luiz Miranda Guimaraes
Sabrina Côté
418-541-1000 poste 3065
|
(EN) A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).
eVOLVE-Lung02
NCT05984277
Actif en recrutement
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI
|
Poumon non à petites cellules |
Dr Marc Trudeau
Sabrina Côté
418-541-1000 poste 3065
|
(EN) A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer
EvoPAR-Prostate01
NCT06120491
Actif en recrutement
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI
|
Prostate |
Dr Jean-Benoit Paradis
Sabrina Côté
418-541-1000 poste 3065
|
(EN) An interventional safety and efficacy phase 1b/2, open-label umbrella study to investigate tolerability, pk, and antitumor activity of ARV-471 (PF-07850327), an oral proteolysis targeting chimera, in combination with other anticancer treatments in participants aged 18 years and over with ER+ advanced or metastatic breast cancer, sub-study B (ARV-471 in combination with ribociclib)
TACTIVE-U
NCT05573555
Actif en recrutement
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI
|
Sein |
Dr José Luiz Miranda Guimaraes
Alexandra Simard
418-541-1000 poste 3163
|
(EN) A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
CAMBRIA-2
NCT05952557
Actif en recrutement
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI
|
Sein |
Dr José Luiz Miranda Guimaraes
Sabrina Côté
418-541-1000 poste 3065
|
Étude de phase 3, ouverte, randomisée, comparant le gédatolisib associé au fulvestrant et avec ou sans palbociclib aux traitements standard chez des patientes atteintes d'un cancer du sein avancé HR-positif, HER2-négatif précédemment traitées avec un inhibiteur CDK4/6 en association avec traitement par inhibiteur non stéroïdien de l'aromatase
VIKTORIA-1
NCT05501886
Actif en recrutement
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI
|
Sein |
Dr José Luiz Miranda Guimaraes
Mary-Denise Dufour
418-541-1000 poste 2823
|
(EN) A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy
pionERA Breast Cancer
NCT06065748
Actif en recrutement
|
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI
|
Sein |
Dr José Luiz Miranda Guimaraes
Mary-Denise Dufour
418-541-1000 poste 2823
|
Groupe d'étude en oncologie du Québec